The therapeutic landscape of obesity is being revolutionized by the unprecedented efficacy of GLP-1 receptor agonists (GLP-1RAs) and dual GIP/GLP-1 receptor agonists. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.